Lymphoma
SYMPHONY-1
A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Trial overview
Clinical Area
Malignant Haematology
Disease / Condition
Lymphoma |
Study Phase
III
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)